fda statement on compounded semaglutide is moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified Compounded "semaglutide" is not FDA-approved
Description
Two pink lines
The good news is that loose skin after weight loss is not a permanent trade-off

[DOI] [PMC free article] [PubMed] [Google Scholar] 30.Schneider EL, Hangasky JA, Fernandez RDV, et al

This route is widely associated with GLP-1 weight management because FDA-approved injectable semaglutide and tirzepatide products are taken once weekly
This scenario was illustrated in our previous dynamic study on GCGR 15

They may help prevent deficiencies that impair metabolic function, essentially removing obstacles rather than actively enhancing pathways
